Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction (STIM-ALC)

27 août 2021 mis à jour par: Assistance Publique - Hôpitaux de Paris

Evaluation of Bilateral HF-rTMS Over DLPFC in add-on to Usual Treatment on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction After Withdrawal

High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

PARTICIPANTS:

Participants with AUD (moderate to mild according to Alcohol Dependance Scale) with executive dysfunctions will be randomized.

DESIGN:

This study is a multicenter pilot double blind randomized controlled trial. After at least seven days of alcohol residential detoxification, executive dysfunctions's participants will be tested. 64 of them with executive dysfunctions will be randomized either in the active rTMS group or in the sham rTMS group. TMS will be performed during hospitalisation over 10 days. rTMS are proposed as an add on to the usual treatment.

INTERVENTION:

20 rTMS (twice a day) will be performed 10 consecutive working days. The target of the rTMS will be the DLPFC (left side in the morning, right side in the afternoon). During each rTMS sessions (active and sham), alcohol related pictures from the Geneva Appetitive alcohol Pictures will be presented.In the active arm, rTMS will be performed with high frequency (20hz, 1500 pulses per session, 110% of motor threshold).In the control group, sham rTMS will be performed.

Participants will be follow up to three months after the end of rTMS treatment.

Type d'étude

Interventionnel

Inscription (Anticipé)

95

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Fanny LEVY, Docteur
  • Numéro de téléphone: 01.42.16.28.94
  • E-mail: fanny.levy@aphp.fr

Sauvegarde des contacts de l'étude

Lieux d'étude

  • France
      • Paris, France, 75013
        • Hôpital Universitaire Pitié-Salpêtrière
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age between 18-75 years
  • Alcohol use disorder according to DSM 5, moderate to mild according to ADS
  • Residential stay for alcohol detoxofication

Exclusion Criteria:

  • Cognitive deficits defined by MoCA <25 (Montreal Cognitive Assessment) performed at least 7days after alcohol detoxification and after at least 12 hours after benzodiazepine cessation
  • History of cerebral stroke
  • DSM-5 substance use disorders other than nicotine and alcohol

  • Contraindication for rTMS :

    • Pregnancy
    • History of epilepsy or seizure
    • Cochlear implants
    • Cardiac pacemaker or intracardiac lines, or metal in the body
  • Clinical history of complicated withdrawal symptoms
  • History of severe head trauma followed by loss of consciousness
  • Actual major depressive episode, schizophrenia according to the MINI (Mini International Neuropsychiatric Interview)
  • Breastfeeding women
  • Actual or history of organic failure including cirrhosis
  • Absence of health insurance; or patient with AME
  • Legal protection (curatorship or tutorship)
  • Deprive of freedom or security measure
  • No adequate mastering of the French language or no ability to consent
  • Major socio-economic problem: homelessness
  • No written informed consent
  • Participation in another interventional study

Secondary inclusion criteria (before randomization):

- Abnormal executive function defined as at least 3 impaired measurements among 19 measurements of 7 tests (Stroop test, Wisconsin test; Trail making test, verbal fluency, 6 elements, Brixton test, Dual task Baddeley test) from the Greffex battery. Each measure will be considered as impaired if it is below 1.65 SD. The procedure and the measurement are standardized. The neuropsychological evaluation will be performed at least seven days after alcohol detoxification and after at least 12 hours after benzodiazepine cessation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active rTMS
Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
Dispositif: Active rTMS
Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
Autres noms:
  • Groupe expérimental
Comparateur placebo: Sham rTMS
Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
Dispositif: Sham rTMS
Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
Autres noms:
  • Groupe de contrôle

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of participants with continuous complete alcohol abstinence
Délai: 1 month after the end of rTMS sessions

Percentage of patients with continuous complete abstinence up to one month after the end of the rTMS treatment.

The abstinence will be assessed using the Alcohol-Time Line Follow Back tool (TLFB). The Alcohol TLFB is a descriptive questionnaire, using a calendar, participants will retrospectively record at M1 the number of days they drank over the 30 days following the end of the rTMS treatment. Continuous complete abstinence will be defined as no day with alcohol consumption over the 30 days.
1 month after the end of rTMS sessions

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of participants with alcohol continuous complete abstinence
Délai: 3 months after the end of rTMS sessions

Percentage of patients with continuous complete abstinence up to 3 months after the end of the rTMS treatment.

The abstinence will be assessed using the Alcohol-TLFB at M1, M2, M3. Continuous complete abstinence will be defined as no day with alcohol consumption over the 90 days.
3 months after the end of rTMS sessions
Number of cumulative abstinence days
Délai: 1 month after the end of rTMS sessions
Alcohol consumption measured by the number of cumulative abstinence days up to 1 month after the end of the rTMS treatment. The number of cumulative abstinence days will be assessed using (TLFB) at M1 and will be calculated by summing the total number of days when no alcohol was consumed over the 30 days.
1 month after the end of rTMS sessions
Number of cumulative abstinence days
Délai: 3 months after the end of rTMS sessions
Alcohol consumption measured by the number of cumulative abstinence days up to 3 months after the end of the rTMS treatment. The number of cumulative abstinence days will be assessed using (TLFB) at M1, M2, M3 and will be calculated by summing the total number of days when no alcohol was consumed over the 90 days.
3 months after the end of rTMS sessions
Time until the first heavy drinking days (HDD)
Délai: 3 months after the end of rTMS sessions
Time until the first heavy drinking days (HDD) up to 3 months. The time, in days, until the first HDD will be assessed using (TLFB) at M1, M2, M3. HDD will be defined as more than 50 (men) or 40 (women) g/day.
3 months after the end of rTMS sessions
Number of heavy drinking days (HDD)
Délai: 1 month after the end of rTMS sessions
Number of heavy drinking days (HDD) up to 1 month. Number of heavy drinking days HDD will be assessed using (TLFB) at M1 and will be calculated by summing the total number of days with HDD over the 30 days. HDD will be defined as more than 50 (men) or 40 (women) g/day.
1 month after the end of rTMS sessions
Number of heavy drinking days (HDD)
Délai: 3 month after the end of rTMS sessions
Number of heavy drinking days (HDD) up to 3 months. Number of heavy drinking days HDD will be assessed using (TLFB) at M1, M2, M3 and will be calculated by summing the total number of days with HDD over the 90 days.. HDD will be defined as more than 50 (men) or 40 (women) g/day.
3 month after the end of rTMS sessions
Time to relapse
Délai: 3 months after the end of rTMS sessions
The time to relapse, in days, will be assessed using (TLFB) at M1, M2, M3. Relapse will be defined as a day with a consumption equal or higher than 50% of initial intake.
3 months after the end of rTMS sessions
Alcohol dependence severity assessed by the Alcohol Dependence Scale (ADS)
Délai: 1 month after the end of rTMS sessions
Alcohol dependence severity will be evaluated with the Alcohol Dependence Scale (ADS). The ADS is a self-administrated 25-items questionnaire (requiring 5 minutes) assessing alcohol withdrawal symptoms, impaired control over drinking, awareness of compulsive drink, increased tolerance and salience of drink-seeking behavior. ADS is initially used to assess a past 12-month period, its instructions can be modified for different time-frame. The ADS will be assessed on previous 4 weeks. This scale is scored out of 47, higher scores are considered worse.
1 month after the end of rTMS sessions
Alcohol dependence severity assessed by the Alcohol Dependence Scale (ADS)
Délai: 3 months after the end of rTMS sessions
Alcohol dependence severity will be evaluated with the Alcohol Dependence Scale (ADS). The ADS is a self-administrated 25-items questionnaire (requiring 5 minutes) assessing alcohol withdrawal symptoms, impaired control over drinking, awareness of compulsive drink, increased tolerance and salience of drink-seeking behavior. ADS is initially used to assess a past 12-month period, its instructions can be modified for different time-frame. The ADS will be assessed on previous 4 weeks. This scale is scored out of 47, higher scores are considered worse.
3 months after the end of rTMS sessions
Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
Délai: At the last day of rTMS sessions
Evaluated by Cue induced Obsessive Compulsive Drinking Scale (OCDS). Cue induced OCDS will be measured after alcohol cues viewing. French version of OCDS is a self-administrated 14-items instrument assessing obsessive and compulsive characteristics of drinking-related thoughts, urge to drink or craving, and ability to resist those thoughts and urges. This scale is scored out of 56, higher scores are considered worse. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures . The same diaporama will be used for all visits in all centers.
At the last day of rTMS sessions
Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
Délai: at 1 month after the end of rTMS sessions
Evaluated by Cue induced Obsessive Compulsive Drinking Scale (OCDS). Cue induced OCDS will be measured after alcohol cues viewing. French version of OCDS is a self-administrated 14-items instrument assessing obsessive and compulsive characteristics of drinking-related thoughts, urge to drink or craving, and ability to resist those thoughts and urges. This scale is scored out of 56, higher scores are considered worse. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures . The same diaporama will be used for all visits in all centers.
at 1 month after the end of rTMS sessions
Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
Délai: at 3 months after the end of rTMS sessions
Evaluated by Cue induced Obsessive Compulsive Drinking Scale (OCDS). Cue induced OCDS will be measured after alcohol cues viewing. French version of OCDS is a self-administrated 14-items instrument assessing obsessive and compulsive characteristics of drinking-related thoughts, urge to drink or craving, and ability to resist those thoughts and urges. This scale is scored out of 56, higher scores are considered worse. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures . The same diaporama will be used for all visits in all centers.
at 3 months after the end of rTMS sessions
Change in Alcohol cue induced craving using a Visual Analogic Scale (VAS)
Délai: From baseline to the last rTMS session after the end of rTMS sessions

Change in cue induced craving Visual Analogic Scale (VAS) from baseline to the last rTMS session.

Cue induced craving VAS will be measured after alcohol cues viewing at baseline and then daily on the morning just before rTMS sessions. The VAS is scored out of 10, higher scores are considered worse. Alcohol cues will be the same as for OCDS.
From baseline to the last rTMS session after the end of rTMS sessions
Alcohol cue induced craving using a Visual Analogic Scale (VAS)
Délai: At 1 month after the end of rTMS sessions
The VAS is scored out of 10, higher scores are considered worse. Alcohol cues will be the same as for OCDS.
At 1 month after the end of rTMS sessions
Alcohol due induced craving using a Visual Analogic Scale (VAS)
Délai: At 3 months after the end of rTMS sessions
The VAS is scored out of 10, higher scores are considered worse. Alcohol cues will be the same as for OCDS.
At 3 months after the end of rTMS sessions
Number of impaired measures on the Grefex batery (executive functions)
Délai: 1 month after the end of rTMS sessions
Executive performance will be evaluated by the number of impaired measures on the Grefex battery : Stroop test, Wisconsin Test, Trail Making Test, verbal fluency, 6 elements, Brixton test and Dual task Baddeley test. Upon these 7 tests, 19 index will be measured (number of errors, time to make the task .). Each measure will be considered as impaired if it is below 1.65 SD. Number of impaired measures will be recorded for each patient.
1 month after the end of rTMS sessions
Stroop test
Délai: 1 month after the end of rTMS sessions
Stroop test will be performed 1 month after the end of the rTMS sessions. The stroop test assess the cognitive inhibition. Time and number of non-corrected errors will be reported for each conditions 1) denomination 2) reading 3) interference.
1 month after the end of rTMS sessions
Trail making test
Délai: 1 month after the end of rTMS sessions
Trail making test will be performed 1 month after the end of the rTMS sessions. The trail making test assess the mental flexibility. Time and number of errors will be reported for the trail making test A and the trail making test B. For this last condition, the number of perserverations will be also reported.
1 month after the end of rTMS sessions
Verbal fluency
Délai: 1 month after the end of rTMS sessions
Verbal fluency will be performed 1 month after the ned of the rTMS sessions. The verbal fluency assess the lexical generation ability. The number of words produced will be reported.
1 month after the end of rTMS sessions
Wisconsin Test
Délai: 1 month after the end of rTMS sessions
Wisconsin test will be performed 1 month after the ned of the rTMS sessions. The Wisconsin test assess the ability of deduction and rules maintenance. Number of correct categories, number of errors and number of perseverations will be reported.
1 month after the end of rTMS sessions
Brixton test
Délai: 1 month after the end of rTMS sessions
Brixton test test will be performed 1 month after the ned of the rTMS sessions. The Brixton test assess the deduction abilify of working rules. Number of errors will be reported.
1 month after the end of rTMS sessions
6 elements
Délai: 1 month after the end of rTMS sessions
6 elements test will be performed 1 month after the ned of the rTMS sessions. The 6 elements test assess the planning and organization ability of the behavior. Ranking score will be reported.
1 month after the end of rTMS sessions
Dual task Baddeley test
Délai: 1 month after the end of rTMS sessions
Dual task Baddeley testwill be performed 1 month after the end of the rTMS sessions. The Dual task Baddeley assess the working memory. Mu index will be reported.
1 month after the end of rTMS sessions
Quality of life assessed by the Quality of life Scale (AQoLS)
Délai: At 1 month after the end of rTMS sessions
Quality of life will be evaluated with Alcohol Quality of Life Scale (AQoLS) French version. This scale is a self-administrated 34-item questionnaire measuring health-related quality of life. The questionnaire explores 7 domains, i.e. activities, relationships, self-esteem, negative emotions, living conditions, control and sleep. The total score was obtained by summing all items, and the theoretical range was therefore 0-102; higher scores are considered better.
At 1 month after the end of rTMS sessions
Quality of life assessed by the Quality of life Scale (AQoLS)
Délai: At 3 months after the end of rTMS sessions
Quality of life will be evaluated with Alcohol Quality of Life Scale (AQoLS) French version. This scale is a self-administrated 34-item questionnaire measuring health-related quality of life. The questionnaire explores 7 domains, i.e. activities, relationships, self-esteem, negative emotions, living conditions, control and sleep. The total score was obtained by summing all items, and the theoretical range was therefore 0-102; higher scores are considered better.
At 3 months after the end of rTMS sessions
% rTMS stimulation performed with optimal stimulation parameters
Délai: At the end of rTMS treatment
Achievement of optimal stimulation parameters will be assessed for each patient by the percentage of sessions performed with the theoretical threshold (110%).
At the end of rTMS treatment
Percentage of rTMS sessions performed.
Délai: At the end of rTMS treatment
Treatment compliance will be assessed by the percentage of rTMS sessions performed.
At the end of rTMS treatment
Percentage of participants experiencing sides effect
Délai: 3 months at the end of rTMS treatment
rTMS security will be assessed by the percentage of patients experiencing sides effects during the study and their nature: seizure induction, transient acute hypomania induction, syncope, transient headache, local pain, neck pain, toothache, paresthesia, transient hearing changes, other.
3 months at the end of rTMS treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Assistance Publique - Hôpitaux de Paris

Les enquêteurs

  • Chercheur principal: Fanny LEVY, Docteur, Assistance Publique - Hôpitaux de Paris

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 septembre 2021

Achèvement primaire (Anticipé)

1 mai 2023

Achèvement de l'étude (Anticipé)

1 juillet 2023

Dates d'inscription aux études

Première soumission

31 juillet 2021

Première soumission répondant aux critères de contrôle qualité

31 juillet 2021

Première publication (Réel)

9 août 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 août 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 août 2021

Dernière vérification

1 mars 2021

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • APHP180582
  • 2020-A00548-31 (Autre identifiant: N° IDRCB)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.

Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Délai de partage IPD

Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Critères d'accès au partage IPD

Researchers who provide a methodologically sound proposal

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Active rTMS

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Tunisia

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner